Testing effectiveness (Phase 2)Study completedNCT01799278
What this trial is testing
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Who this might be right for
Small Cell Prostate CancerNeuroendocrine Prostate CancerProstate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers
Weill Medical College of Cornell University 60